Preclinical Radioligand Therapy to Advance Radiopharmaceuticals

From radiolabeling and biodistribution to dosimetry and efficacy in diverse animal models, Perceptive Discovery delivers integrated, translatable data to accelerate your radiopharmaceutical pipeline from concept to clinic.

Home

Preclinical Radioligand Therapy

The Leading Preclinical Imaging Partner for Radiopharmaceutical Development

Perceptive Discovery offers comprehensive preclinical RLT services to support the discovery and development of radiopharmaceutical therapies. We work with biotech and pharmaceutical teams to design and execute custom studies that generate the translational data needed for IND submission and clinical advancement.

Our team of radiochemists, pharmacologists, cancer biologists, and imaging scientists bring deep expertise across a broad spectrum of isotopes, modalities, and therapeutic platforms. Whether developing a novel targeted radiotherapeutic or a companion diagnostic, we streamline radiolabeling, dosimetry, efficacy, and image analysis—all under one roof.

With over 900+ preclinical RLT studies supported, and 50+ IND-enabling dosimetry studies, we are a proven partner in bringing first-in-class radiopharmaceuticals to the clinic.

Global infrastructure: 6 preclinical labs with integrated radiochemistry centers
Full suite of multi-modality imaging: PET, SPECT, MRI, CT, IVIS, CFT
Experience across tumor types and administration routes
Extensive Alpha/Beta Emitter experience:
- Alpha Emitters: ²²⁵Ac, ²¹²Pb, ²¹¹At
- Beta Emitters: ¹⁷⁷Lu, ⁶⁷Cu, ¹⁶¹Tb, ¹³¹I, ⁹⁰Y

End-to-End Support for Radiopharmaceutical Development

With over 900+ preclinical RLT studies supported, and 50+ IND-enabling dosimetry studies, we are a proven partner in bringing first-in-class radiopharmaceuticals to the clinic.

Radiolabeling & Chemistry Services

Custom radiolabeling of small molecules, peptides, antibodies, nucleic acids, cells, and nanoparticles
- Isotope platforms for PET, SPECT, and therapy: ¹⁸F, ^89Zr, ^64/67Cu, ^68Ga, ¹⁷⁷Lu, ²²⁵Ac, ^212/203Pb, ^131/125I, ²¹¹At
- Chelation chemistry and isotope pairing for theranostic applications
- In-house purification, QC, and stability testing
Biodistribution & PK/PD Imaging
Quantification of tumor and tissue uptake using matched diagnostic/therapeutic pairs (e.g., ²⁰³Pb/²¹²Pb, ^89Zr/²²⁵Ac, ¹¹¹In/²²⁵Ac, ¹⁸F/²¹¹At)
Evaluate systemic distribution, target specificity, and clearance
Longitudinal studies across small and large animal models utilizing multiple routes of administration

Dosimetry & IND-Enabling Studies

Regulatory-grade dosimetry using direct and surrogate isotope imaging
Species: mouse, rat, NHP (cynomolgus monkey)
Dose estimation and organ toxicity prediction
Evaluation of radionuclide daughter translocation and clearance

Efficacy in In Vivo Tumor Models

Monitor tumor regression and survival outcomes
Assess in-life and endpoint toxicity with hematology (CBC) and clinical chemistry biomarkers
Compare candidate efficacy to standard of care
Correlate therapeutic response with dosimetry and biomarker expression

Preclinical imaging scan of small animals showing skeletal structure with highlighted regions of radiotracer uptake in bright red, yellow, and purple tones, indicating areas of biological activity.

Anti tumour-muc-1 antibody labelled with DOTA and imaged in mice using 111In.
Kelly V.J. et al Theranostics 2020, Vol. 10, Issue 15

Two-panel scientific graph showing tumor growth and survival in mice after treatment. Panel A (left): Line graph of change in tumor volume (%) versus days post injection. Mice treated with ^225Ac–DOTA–hTAB004 (red lines) show minimal tumor growth, with tumor volume remaining near baseline. Mice treated with DOTA–hTAB004 (blue lines) show sharp increases in tumor volume over time, reaching above 1500% by around day 20–35. Panel B (right): Kaplan–Meier survival curve of survival duration (days) versus survival percentage. All mice treated with ^225Ac–DOTA–hTAB004 (red line) survive through the study (100% survival up to ~50 days). Mice treated with DOTA–hTAB004 (blue line) show declining survival starting around day 17, with 0% survival by day 35. Legend indicates red for ^225Ac–DOTA–hTAB004 and blue for DOTA–hTAB004.

Mice treated with 225Ac-labelled anti tumour-muc-1 antibody A) Tumor volume in animals administered with 225Ac-DOTA-hTAB004 (red) compared to control animals administered DOTA-hTAB004 (blue) as monitored for the duration of the study. Intra-group comparisons of percentage change in tumor volume at each study day; * P<0.05, # P<0.01, ^ P<0.001. (B) Kaplan-Meier survival curves showing 100% survival in treatment group until the end of the study (D=48; red) and 0% survival in control group (blue).
Kelly V.J. et al Theranostics 2020, Vol. 10, Issue 15

How Can We Help?

Reach out today and one of our solution experts will be in touch to learn about your specific needs.

"*" indicates required fields

X/Twitter

This field is for validation purposes and should be left unchanged.

First name*

Last name*

Job title*

Company name*

Your Location*

State

Business email*

CAPTCHA

By subscribing, you consent to receive emails from Perceptive. We respect your privacy and you can manage your communication preferences anytime. You can find the Perceptive privacy policy here.

Smiling woman with curly hair wearing glasses and a beige sweater, working on a laptop, with abstract blue and white geometric shapes in the background.